共 52 条
[1]
Liu J(2023)Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial Am Heart J 257 93-102
[2]
Wang B(2023)Highlights of cardiovascular disease prevention studies presented at the 2022 American Heart Association Scientific Sessions Curr Atheroscler Rep 25 31-41
[3]
Li Y(2023)Highlights of cardiovascular disease prevention studies presented at the 2023 American College of Cardiology Conference Curr Atheroscler Rep 25 309-321
[4]
Yan X(2022)Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nat Med 28 2083-2091
[5]
Ge J(2023)Zilebesiran, an RNA Interference Therapeutic agent for hypertension N Engl J Med 389 228-238
[6]
Li J(2022)PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study BMC Med 20 13-2192
[7]
Gupta K(2015)The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association Circulation 132 2167-253
[8]
Hirsch JR(2015)Genetics of familial hypercholesterolemia Curr atheroscler Rep 147 242-975
[9]
Kalsi J(2023)Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models Circulation 151 969-2116
[10]
Patel V(2022)A mistake not to be repeated: what can we learn from the underutilization of statin therapy for efficient dissemination of cardioprotective glucose lowering agents? Currently Cardiol Rep 373 2103-undefined